Overview

TMC207 +/- Rifabutin/Rifampin

Status:
Completed
Trial end date:
2012-05-23
Target enrollment:
Participant gender:
Summary
Evaluation of effect of rifampin or rifabutin on single dose PK of TMC207 in healthy volunteers
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Bedaquiline
Diarylquinolines
Rifabutin
Rifampin